Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04305067
Previous Study | Return to List | Next Study

PRECISE: Pancreatic Cancer and Exercise

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04305067
Recruitment Status : Not yet recruiting
First Posted : March 12, 2020
Last Update Posted : March 12, 2020
Sponsor:
Collaborators:
Pancreatic Cancer UK
Belfast Health and Social Care Trust
Information provided by (Responsible Party):
Gillian Prue, Queen's University, Belfast

Brief Summary:
The purpose of this study is to establish the feasibility of delivering a prescribed, individualised supervised aerobic and resistance exercise programme during adjuvant therapy, to improve survival and reduce symptom burden in pancreatic cancer

Condition or disease Intervention/treatment Phase
Pancreas Adenocarcinoma Other: Exercise Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: PRECISE: PancREatic Cancer and Individualised Supervised Exercise: a Feasibility Study
Estimated Study Start Date : March 1, 2020
Estimated Primary Completion Date : July 31, 2021
Estimated Study Completion Date : July 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Supervised aerobic and resistance exercise
16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
Other: Exercise
Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.




Primary Outcome Measures :
  1. Feasibility - recruitment: number of participants that agree to participate or are excluded [ Time Frame: At baseline ]
    The number of participants that agree to participate or are excluded

  2. Feasibility - attrition: number of participants that withdraw from the study [ Time Frame: At conclusion of the 16 week exercise intervention ]
    The number of participants that withdraw from the study

  3. Feasibility - adherence to the exercise intervention: percentage of participants adhering to the exercise intervention [ Time Frame: At conclusion of the 16 week exercise intervention ]
    Determine the percentage of participants adhering to the exercise intervention

  4. Feasibility - participant experience: semi-structured interviews [ Time Frame: At conclusion of the 16 week exercise intervention ]
    Determined by qualitative evaluation, using semi-structured interviews to assess experiences, accessibility and acceptability of the exercise intervention


Secondary Outcome Measures :
  1. Anthropometric assessment [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Height will be measured in cm and body weight in k, which will be combined to report BMI in kg/m (squared).

  2. Hip and waist circumference analysis [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Hip and waist circumference will be measured in cm.

  3. Functional muscle endurance assessment [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    The amount of repetitions achieved during a 30 second sit-to-stand test will be recorded.

  4. Physical fitness assessment [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Distance covered in meters during a six minute walk test will be recorded.

  5. Perceived physical activity levels [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Patients will complete an International Physical Activity Questionnaire (IPAQ-SF). This questionnaire will comprise 4 generic items to obtain comparable health-related physical activity. Patients will detail the number of days, hours and minutes that they undertake (1) vigorous exercise (2) moderate exercise (3) walking exercise and (4) sitting. Total physical activity will be generated and monitored for improvement or decline. Higher reported scores indicate higher levels of self-reported physical activity.

  6. Cancer-related fatigue by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Fatigue will be measured by the Functional Assessment of Cancer Therapy - Fatigue (FACIT-Fatigue) questionnaire. Patients will score several fatigue items over the past 7 days on a scale (0 = not at all; 4 = very much), generating a total (0 - 52) with higher scores linked to greater quality of life.

  7. Patient rated pain by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Pain will be measured using the Brief Pain Inventory (BPI). Pain is scored on a scale 0 - 10, with higher scores indicating higher pain levels.

  8. Health related quality of life by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Quality of life will be measured by the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. This questionnaire is scored on a scale of 0 - 4, with 0 indicating not at all, and 4 indicating very much. Higher scores indicate poorer quality of life.

  9. Health related quality of life by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]
    Quality of life will be measured by the EuroQOL Five Dimension Questionnaire (EQ5D). Patients will select a level of difficulty (I have no - I have extreme) on that particular days health for mobility, self-care, usual activities, pain / discomfort and anxiety / depression. Patients will then rate 'how good' or 'how bad' their health is on that day using a 100 point scale (0 = worst health you can imagine; 100 = best health you can imagine).

  10. Health economics [ Time Frame: At 16 weeks ]
    Health resource use will be evaluated by a Health Economics Questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age ≥ 18 years
  • histologically proven pancreatic ductal adenocarcinoma
  • complete macroscopic resection (R0 or R1 resection)
  • patients recovering from surgery in time for chemotherapy to be delivered with adjuvant intent
  • prior malignancy active within the previous 3 years other than locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • deemed medically fit by treating team to participate in exercise programme
  • able to provide informed consent.

Exclusion Criteria:

  • Macroscopically remaining tumour (R2 resection or tumour node metastasis (TNM) stage IV disease)
  • Pre-existing cardiac conditions; Congestive heart failure or recent serious cardiovascular event
  • Chest pain while undertaking physical activity
  • Any related co-morbidities (diabetes; unstable angina; degenerative neuromuscular disease; mental health disorders; substance abuse)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04305067


Contacts
Layout table for location contacts
Contact: Gillian Prue, PhD 02890972345 g.prue@qub.ac.uk
Contact: Dominic O'Connor, PhD 02890975213 dominic.oconnor@qub.ac.uk

Sponsors and Collaborators
Queen's University, Belfast
Pancreatic Cancer UK
Belfast Health and Social Care Trust
Investigators
Layout table for investigator information
Principal Investigator: Richard Turkington, MD Queens University
Layout table for additonal information
Responsible Party: Gillian Prue, Senior lecturer in chronic illness, Queen's University, Belfast
ClinicalTrials.gov Identifier: NCT04305067    
Other Study ID Numbers: B19/35
First Posted: March 12, 2020    Key Record Dates
Last Update Posted: March 12, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No